Literature DB >> 12619546

Nasopharyngeal cancer.

Anthony T C Chan1, Peter M L Teo, Philip J Johnson.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12619546     DOI： 10.1007/0-306-48060-3_11

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  4 in total

1.  Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.

Authors:  Jianwei Zhang; Wenfeng Fang; Tao Qin; Yunpeng Yang; Shaodong Hong; Wenhua Liang; Yuxiang Ma; Hongyun Zhao; Yan Huang; Cong Xue; Peiyu Huang; Zhihuang Hu; Yuanyuan Zhao; Li Zhang
Journal:  Med Oncol       Date:  2015-02-22       Impact factor: 3.064

2.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

3.  The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Shu-Xiang Ma; Ting Zhou; Yan Huang; Yun-Peng Yang; Jian-Hua Zhan; Ya-Xiong Zhang; Zhong-Han Zhang; Yuan-Yuan Zhao; Wen-Feng Fang; Yu-Xiang Ma; Li-Kun Chen; Hong-Yun Zhao; Li Zhang
Journal:  Ann Transl Med       Date:  2018-06

4.  Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.

Authors:  Yan Huang; Ying Tian; Yuanyuan Zhao; Cong Xue; Jianhua Zhan; Lin Liu; Xiaobo He; Li Zhang
Journal:  Cancer Commun (Lond)       Date:  2018-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.